Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Breast Center, |
RCV001254333 | SCV001430317 | likely pathogenic | Hereditary breast ovarian cancer syndrome | 2020-05-01 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV003584827 | SCV004360126 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-22 | criteria provided, single submitter | clinical testing | This missense variant replaces glutamine with proline at codon 1721 of the BRCA1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). This variant has been reported to be loss-of-function in a haploid cell proliferation assay (PMID: 30209399). This variant has been reported in individuals affected with breast cancer (PMID: 32803532). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Brotman Baty Institute, |
RCV001076517 | SCV001242285 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |